Heterologous mRNA-based COVID-19 booster strategies: Comment

Heterologous mRNA-based COVID-19 booster strategies: Comment

Bibliographic Details
Main Authors:	Sora Yasri, Viroj Wiwanitkit
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-01-01
Series:	Human Vaccines & Immunotherapeutics
Online Access:	http://dx.doi.org/10.1080/21645515.2023.2174758

Similar Items

Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment”
by: Rituparna Das, et al.
Published: (2023-01-01)

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
by: Rituparna Das, et al.
Published: (2023-01-01)

Comment on "Reactogenicity Study of mRNA COVID-19 Vaccine"
by: Amnuay Kleebayoon, et al.
Published: (2023-07-01)

Comments on “Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination”
by: Rujittika Mungmunpuntipantip, et al.
Published: (2023-01-01)

Heterologous COVID-19 vaccination in pregnant women: Comment
by: Pathum Sookaromdee, et al.
Published: (2023-08-01)

“Acute psychosis induced by mRNA-based COVID-19 vaccine in adolescents: A pediatric case report”: Comment
by: Amnuay Kleebayoon, et al.
Published: (2023-11-01)

Myocarditis and COVID-19 mRNA vaccination
by: Rujittika Mungmunpuntipantip, et al.
Published: (2022-08-01)

Imaging and COVID-19
by: Sora Yasri, et al.
Published: (2020-09-01)

Willingness of college students to receive COVID-19 heterologous vaccination: Comment
by: Amnuay Kleebayoon, et al.
Published: (2023-01-01)

Rhinorrhea in COVID-19: Observation
by: Sora Yasri, et al.
Published: (2020-01-01)

Hemoptysis in COVID-19: Observation
by: Sora Yasri, et al.
Published: (2020-01-01)

Clinical presentation of paragonimiasis in 73 published Thai cases: summary and comment on the change of disease pattern
by: Sora Yasri, et al.
Published: (2019-01-01)

Change of malaria incidence after COVID-19 lockdown: An observation
by: Sora Yasri, et al.
Published: (2023-01-01)

Risk-prediction model for COVID-19 infection in dialysis patients
by: Sora Yasri, et al.
Published: (2020-01-01)

COVID-19 and face mask insufficiency crisis: A note
by: Sora Yasri, et al.
Published: (2020-01-01)

New COVID-19 vaccine: What about cost and utility?
by: Sora Yasri, et al.
Published: (2022-01-01)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
by: Yun Shan Goh, et al.
Published: (2022-01-01)

Troponina-T e Peptídeo Natriurético tipo B na COVID-19
by: Sora Yasri, et al.
Published: (2021-04-01)

Sustainable materials and COVID-19 detection biosensor: A brief review
by: Sora Yasri, et al.
Published: (2022-01-01)

Sharing cigarette smoking and COVID-19 outbreak in a party group
by: Sora Yasri, et al.
Published: (2020-01-01)

Common place for COVID-19 local spreading: Observation from Thailand
by: Sora Yasri, et al.
Published: (2020-01-01)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
by: Oleguer Parés-Badell, et al.
Published: (2022-07-01)

Multi-epitope mRNA vaccine candidate to combat HMPV virus: Comment
by: Hinpetch Daungsupawong, et al.
Published: (2024-12-01)

COVID-19 incidence and Bacillus Calmette-Guerin Vaccination coverage rate: Observation
by: Sora Yasri, et al.
Published: (2022-01-01)

Expected usefulness of the third dose of COVID-19 vaccine for organ transplant recipient adolescent
by: Sora Yasri, et al.
Published: (2023-01-01)

Public tourist bus, tourist bus driver, and COVID-19 infection: A note
by: Sora Yasri, et al.
Published: (2020-01-01)

Comment on “Heterologous adenovirus‐vector/messenger RNA regimen, humoral response and liver transplant recipients”
by: Pathum Sookaromdee, et al.
Published: (2022-12-01)

COVID-19, Antiphospholipid Syndrome and Thrombosis
by: Sora Yasri PhD, et al.
Published: (2020-08-01)

Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
by: Pimsiri Sripongpun, et al.
Published: (2023-09-01)

Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia
by: Gatot Soegiarto, et al.
Published: (2023-06-01)

Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial
by: Daniel Mrak, et al.
Published: (2022-09-01)

Comment on ““Multi inflammatory syndrome following first dose of m-RNA COVID-19 vaccination”
by: Pathum Sookaromdee, et al.
Published: (2022-04-01)

D-dimer, COVID-19 and Diabetes: A Correspondence
by: Sora Yasri PhD, et al.
Published: (2021-11-01)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
by: Zhenhao Fang, et al.
Published: (2022-06-01)

Durability of immune responses to mRNA booster vaccination against COVID-19
by: Prabhu S. Arunachalam, et al.
Published: (2023-05-01)

Ethical concerns regarding heterologous COVID-19 vaccine administration
by: Somsri Wiwanitkit, et al.
Published: (2024-12-01)

Concurrent administration of COVID-19 vaccine and seasonal influenza vaccine: safe according to a small observation
by: Sora Yasri, et al.
Published: (2023-01-01)

Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment
by: Rujitika Mungmunpuntipantip, et al.
Published: (2023-08-01)

Gloves and Ebola virus: a consideration of the penetration possibility based on nanostructure consideration
by: Sora Yasri, et al.
Published: (2015-03-01)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
by: Gen Li, et al.
Published: (2022-07-01)